Phase II study in advanced sarcoma: randomized trial of pyrazofurin versus combination cyclophosphamide, doxorubicin, and cis-dichlorodiammineplatinum(II) (CAP).
Twenty-eight patients with various histologic types of measurable metastatic sarcoma were randomly assigned to receive treatment with combination cyclophosphamide, doxorubicin (Adriamycin), and cis-dichlorodiammineplatinum(II) (CAP) or the single-agent, pyrazofurin. Patients who failed one arm of the protocol were eligible for cross-over treatment. Six of 24 patients treated with CAP achieved objective tumor regressions (25%), with a median duration of 11 months. None of 21 patients receiving pyrazofurin achieved a response. CAP is an effective, well-tolerated combination for the treatment of advanced sarcoma.
D000577:Amides; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D011720:Pyrazoles; D012263:Ribonucleosides / Q000008:administration & dosage*; D012266:Ribose; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*
D000577:Amides; D000970:Antineoplastic Agents; D011720:Pyrazoles; D012263:Ribonucleosides; C002997:pyrazofurin; D012266:Ribose; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin